Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSH | P09668 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039215 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTSBMDM4TP53 | |
| SCHEMBL29664082 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTSBMDM4TP53 | |
| SCHEMBL13323320 | 1.00 | CASP3 (0.57) | CASP3KMT2ACTSBMDM4TP53 | |
| SCHEMBL29426432 | 0.89 | CASP3 (0.49) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL24785654 | 0.88 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL30291780 | 0.88 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL24785651 | 0.88 | CASP3 (0.48) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL13323300 | 0.87 | CASP3 (0.49) | CASP3KMT2ACTSBMDM4TP53 | |
| SCHEMBL4552562 | 0.86 | CASP3 (0.71) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL31498750 | 0.86 | CASP3 (0.71) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9605024-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-9303065-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-11 | — | — | US | disclosed |
| US-8927688-B2 | PAR4 agonist peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-31 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CASP3 282/4885KMT2A 3449/4885CTSB 124/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | CASP3 282/4885KMT2A 3449/4885CTSB 124/4885 |
| US-20130289238-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | CASP3 1091/4885KMT2A 2954/4885CTSB 662/4885 |
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | CASP3 535/4885KMT2A 2089/4885CTSB 874/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | CASP3 3617/4885KMT2A 3513/4885CTSB 1790/4885 |
| US-20150158910-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | CASP3 1091/4885KMT2A 2954/4885CTSB 662/4885 |
| US-20160304560-A1 | PAR4 AGONIST PEPTIDES | F2RL3, F2R, F2RL1 | CASP3 1091/4885KMT2A 2954/4885CTSB 662/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CASP3 282/4885KMT2A 3449/4885CTSB 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.